Browse studies, page 1090
Page 1090 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Effects on major adverse cardiovascular events (MACE) in persons treated with sotagliflozin: Prespecified pooled analyses of the Phase 3 type 2 diabetes program Global Cardiology Science & Practice, 2026
- Sglt2 inhibitors and outcomes in patients with diabetes after durable lvad implantation: a multicenter real-world cohort study European Journal of Heart Failure, 2026
- Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure European Journal of Heart Failure, 2026
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus medRxiv, 2026
- SGLT2 inhibitors Use in Kidney Disease: What Did We Learn? American Journal of Physiology. Endocrinology and Metabolism, 2025
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis PLoS ONE, 2016
- SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials Healthcare, 2022
- P1500Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA-HEART cardiolink-6 trial European Heart Journal, 2019
- Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis HORMONES, 2023
- Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Hemoglobinand Hematocrit: A Retrospective Analysis (SGLT-2 Inhibitors &Hemoconcentration) Journal of Diabetes Research Review & Reports, 2026
- SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence International Journal of Hepatology, 2026
- Efficacy and Safety of Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis Korean Circulation Journal, 2026
- Abstract 4361602: SGLT2 Inhibitors in LVAD Patients: A Multi-Center Propensity-Matched Cohort Analysis Circulation, 2025
- Abstract 12476: Dapagliflozin versus Empagliflozin and the Risk for Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Nationwide Population-Based Study Circulation, 2022
- Long-Term Use of Empagliflozin vs. DPP4 Inhibitors Mitigates eGFR Slopes in Patients With Type 2 Diabetes: Real-World Evidence Journal of the American Society of Nephrology, 2022
- #4139 effects of empagliflozin on fluid overload in chronic kidney disease: an empa-kidney bioimpedance substudy Nephrology, Dialysis and Transplantation, 2023
- Retinal and optic nerve measures after initiation of empagliflozin plus metformin versus metformin alone in early type 2 diabetes: a prospective observational comparative study Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026
- Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series Medwave, 2024
- Systolic plood pressure response to ASi BI 690517 with and without empagliflozin in CKD European Heart Journal, 2024
- Comparative effectiveness and prescribing patterns of dapagliflozin vs empagliflozin in type 2 diabetes patients: a target trial emulation Diabetes Research and Clinical Practice, 2025
- Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study Medicina, 2025
- Empagliflozin alleviates type 2 diabetic renal fibrosis by inhibiting SLC7A7-mediated ferroptosis Diabetology & Metabolic Syndrome, 2025
- Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 Diabetes Care, 2021
- Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved Nature Medicine, 2022
- Preoperative empagliflozin and ventricular remodeling after coronary artery bypass grafting in type 2 diabetes: a prespecified analysis of the POST-CABGDM randomized trial Diabetology & Metabolic Syndrome, 2026
- Clinical similarity, economic divergence: cost-effectiveness and population health implications of dietary, pharmacological, and exercise interventions in older adults with type 2 diabetes: a secondary analysis of a randomized controlled trial BMC Geriatrics, 2026
- OR2805 Plasma Sodium Increase Is Associated With An Increase In Bone Formation In Outpatients With Chronic SIAD—A Predefined Secondary Analysis Of The SANDx Trial Journal of the Endocrine Society, 2023
- Abstract 17157: The SGLT2 Inhibitor Empagliflozin Ameliorates Interstitial Myocardial Fibrosis and Aortic Stiffness in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction: A Secondary Analysis of the EMPATROPISM Trial 2020
- Abstract 17275: The SGLT2 Inhibitor Empagliflozin Ameliorates Left Atrial Dilatation in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction: A Secondary Analysis of the EMPATROPISM Trial Circulation, 2020
- Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis Croatian Medical Journal, 2025
- Finerenone in Asian patients with diabetic kidney disease: evaluating the evidence for "better efficacy" Clinical kidney journal, 2026
- Uniform efficacy of SGLT2 inhibitors across the ejection fraction spectrum and in high-risk patients with HFpEF: a prespecified pooled analysis Frontiers in cardiovascular medicine, 2026
- Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial Journal of the American Heart Association, 2026
- Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights Cureus, 2026
- Impact of Ertugliflozin on Cardiac Structure and Function in Patients with ICDs/CRT-Ds Assessed by Echocardiography: A Post Hoc Sub-Analysis of the ERASe Trial Journal of clinical medicine, 2025
- SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI. ESC heart failure, 2025
- Enhancing evidence-based guidelines using trial emulation in electronic health records: Real-world effects of empagliflozin in people with type 2 diabetes medRxiv, 2025
- Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed Glomerular diseases, 2026
- Treatment of Youth-Onset Type 2 Diabetes: Focus on SGLT-2 Inhibitor Use Pediatric diabetes, 2026
- Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review Cureus, 2025
- Dual SGLT1/2 inhibition with sotagliflozin improves cardiac function and metabolism in type 2 diabetic mice npj metabolic health and disease, 2026
- Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review International journal of general medicine, 2026
- Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Anemia in Patients with Chronic Kidney Disease: A Pre-Post Observational Analysis Medical sciences (Basel, Switzerland), 2026
- Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
- Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes Physiological reports, 2025
- Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations Frontiers in cardiovascular medicine, 2026
- Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls Current heart failure reports, 2026
- Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review Diabetes, obesity & metabolism, 2026
- Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes BMJ open diabetes research & care, 2026
- Beyond Hyperglycemia: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction US cardiology, 2026
- Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection Biomedicines, 2026
- Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction in Patients Without Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials Clinical Medicine Insights. Cardiology, 2026
- Practical Guidance on Implementation of Guideline-Directed Medical Therapy in the Management of Heart Failure: Expert Opinion From the Middle East and Africa Region Journal of the American Heart Association, 2026
- Effects of heart failure pharmacotherapy on natriuresis and diuresis: A narrative review Heart failure reviews, 2026
- Risk factor obesity: treatment standard Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
- Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation Hepatology forum, 2026
- Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal Diabetology & metabolic syndrome, 2026
- Serum Uric Acid in Chronic Kidney Disease as a Marker of Risk or a Modifiable Driver of Progression: A Systematic Review Cureus, 2026
- Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease Diabetes, obesity & metabolism, 2026
- Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake Scientific reports, 2026
- Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence ESC heart failure, 2025
- Cardiovascular Implications of Diabetes Mellitus: A Systematic Literature Review Cureus, 2026
- Contemporary management of advanced chronic kidney disease: An evidence-based review European journal of internal medicine, 2026
- Efficacy and Safety of SGLT2 Inhibitors and Sotagliflozin in Heart Failure: A Systematic Review and Meta-Analysis of 59 Randomized Controlled Trials Cureus, 2026
- Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Nephropathy: A Systematic Review and Meta-Analysis Cureus, 2026
- Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far? Frontiers in clinical diabetes and healthcare, 2025
- PRO/CON debate: nonsteroidal versus steroidal mineralocorticoid receptor antagonists in chronic kidney disease: progress, pragmatism, and remaining uncertainties Clinical kidney journal, 2026
- Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure ESC heart failure, 2026
- Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review Heart failure reviews, 2026
- Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment? Pharmaceutics, 2025
- Evidence on SGLT2 Inhibitors' Efficacy in Older and Frail Patients Journal of clinical medicine, 2026
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies Gut and liver, 2026
- Heart failure evidence update 2026 Heart failure reviews, 2026
- Efficacy of SGLT2 inhibitors in patients recently hospitalized for heart failure: an exploratory prespecified pooled analysis of the DELIVER and EMPEROR-preserved trials Frontiers in cardiovascular medicine, 2026
- Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications Journal of clinical medicine, 2026
- Use of vericiguat in the VICTOR trial: a study that is difficult to interpret European heart journal supplements : journal of the European Society of Cardiology, 2026
- SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis Arteriosclerosis, thrombosis, and vascular biology, 2026
- SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendations The British journal of cardiology, 2026
- Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes Journal of clinical medicine, 2026
- eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes Diabetes, metabolic syndrome and obesity : targets and therapy, 2026
- Finerenone in Asian Patients with Type 2 Diabetes Mellitus and Albuminuric Chronic Kidney Disease: From Evidence to Implementation Diabetes & metabolism journal, 2026
- Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction Heart failure reviews, 2026
- The urinary albumin-to-creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease Journal of internal medicine, 2026
- Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial JAMA neurology, 2020
- Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials Expert opinion on drug safety, 2020
- A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage JAMA neurology, 2020
- Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial Journal of the American Heart Association, 2020
- Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. Diabetes, obesity & metabolism, 2021
- Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes Cardiovascular diabetology, 2021
- Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes EClinicalMedicine, 2022
- Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled JAMA cardiology, 2022
- Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial European journal of heart failure, 2023
- Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria American journal of preventive cardiology, 2023
- Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes Journal of diabetes and its complications, 2023
- Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial Kidney medicine, 2024
- Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin Scientific reports, 2024
- Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE. European journal of heart failure, 2024
- Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial CJC open, 2024
- Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status Kidney international reports, 2026
- Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials Diabetes research and clinical practice, 2017
